Open AccessSevere Inflammatory Ophthalmopathy in a Euthyroid Patient during Nivolumab Treatment
Author(s) -
Pauline Campredon,
P Imbert,
C. Mouly,
Solange Grunenwald,
Julien Mazières,
Philippe Caron
Publication year - 2018
Publication title -
european thyroid journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.23
H-Index - 10
eISSN - 2235-0802
pISSN - 2235-0640
DOI - 10.1159/000485742
Subject(s) - medicine , chemosis , nivolumab , euthyroid , ptosis , thyroid cancer , thyroid , surgery , gastroenterology , cancer , immunotherapy
Nivolumab is a promising treatment in patients with advanced malignancies. Among immune-related adverse events, autoimmune thyroid disorders are frequently reported.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom